A Study of TAF in Combination With PEG-IFN and Hepalatide in Subjects With Chronic Hepatitis B

Inclusion Criteria:

• 1. 18 years ≤ age ≤ 60 years, both sexes.

2. HBsAg (+) or HBV DNA (+) for ≧ 6 months
3. HBeAg(-)
4. on stable treatment for NAs for ≧ 2 years.
5. HBV DNA <LLQD (lower limit of quantitative detection) at screening.
6. ULN<ALT<10×ULN.
7. total serum bilirubin <2×ULN.
8. no childbirth plan within 2 years and agree to take effective contraceptivemeasures throughout the treatment period and within 3 months after the last dose, andthat the woman is not pregnant or breastfeeding.
9. have not participant in another clinical trial within 3 months
10. have good compliance with the study protocol.
11. the subject understands and agrees to sign the informed consent form

Exclusion Criteria:

• 1. contraindications to pegylated interferon therapy, such as major depression,epilepsy, autoimmune disease, uncontrolled thyroid abnormal thyroid function, etc.

2. clinical evidence of cirrhosis: e.g., definite cirrhosis on imaging such asabdominal ultrasound and CT; liver biopsy with Metavir fibrosis score of 4; clinicaldiagnosis of cirrhosis by the investigator.
3. decompensated liver disease: PT > 1.2 x ULN, serum albumin < 35 g/L
4. liver function Child-Pugh grade B-C or score >6
5. any of the following.
6. history of decompensated liver disease (ascites, hepatic encephalopathy, varicealhemorrhage, hepatorenal syndrome, etc.)
7. history of severe heart disease (including unstable or uncontrolled heart diseasewithin 6 months)
8. uncontrolled epilepsy, severe mental illness or history of severe mental illness
9. history of organ transplantation.
10. diabetes mellitus and hypertension that are not effectively controlled
11. autoimmune diseases, immune-related extrahepatic manifestations (vasculitis,purpura, nodular arteritis, peripheral neuropathy and glomerulonephritis) ,thyroid disease, malignancy, and immunosuppressive therapy.
12. with underlying diseases such as malignancy, severe infections, heart failure andchronic obstructive pulmonary disease, and other serious diseases diseases.
13. History of alcohol or drug abuse.
14. creatinine clearance <60mL/min.
15. co-infected with hepatitis A, C, D or E virus, HIV infection.
16. subjects who must be treated with anti-HBV nucleoside (acid) analogs other than TAFduring the treatment period.
17. subjects who have used interferon within 6 months prior to the screening
18. subjects with positive anti-HBV Pre-S1 antibody.
19. Abnormal blood tests: white blood cell count < 3×10^9 /L, neutrophil count < 1.5×10^9/L , platelets < 60×10^9 /L .
20. Positive pregnancy test in women.
21. patients who are taking drugs prohibited by the test and cannot be discontinued
22. patients with known allergy to the test drug or the underlying treatment drug
23. other laboratory or ancillary tests are clearly abnormal and unsuitable forparticipation in the test.